220 likes | 428 Views
PRET Patients P rone to R ecurrence after E ndovascular T reatment. XIX SYMPOSIUM NEURORADIOLOGICUM. Angiographic recurrences risk factors Size 10mm Recurrent aneurysm. Background and purpose. 50% of recurrence. These aneurysms are poorly represented in clinical trials
E N D
PRET PatientsPronetoRecurrence afterEndovascularTreatment XIX SYMPOSIUM NEURORADIOLOGICUM
Angiographic recurrences risk factors Size 10mm Recurrent aneurysm Background and purpose 50% of recurrence
These aneurysms are poorly represented in clinical trials HELPS study included some large aneurysms (~25%) and no recurrent aneurysms Background and purpose
New coils have been designed to preserve the safety while improving on long-term efficacy No scientific evidence Some concerns have been raised about the safety of hydrocoils in large aneurysms Background and purpose
The use of hydrogel-coated coils in patients with large aneurysms or presenting major recurrences after a previous endovascular treatment decreases the recurrence rate from 50% to 32% at 18 months as compared to bare platinum coils Primary hypothesis
The number of adverse events is similar in both groups. Morbidity and mortality related to treatment remains unchanged Secondary hypothesis
Design Multicentre, randomized, controlled trial with concealed allocation Two cohorts, 250 subjects each, independently randomized PRET 1 : One ruptured or unruptured aneurysm, never treated, 10 mm or larger PRET 2 : A major (i.e. requiring retreatment) recurrence after previous coiling It is possible for a site to recruit selectively in either cohort, depending on site participation in other competing trials
Design • Inclusion Criteria • PRET-1 or PRET-2 lesion • Anatomy of lesion is such that treatment is possible with either type of coil • Endovascular physician is indifferent to the use of either type of coil • Patient is 18 or older • Life expectancy is more than 2 years • Exclusion criteria • Other aneurysms requiring treatment during the same session • Associated cerebral AVMs • Parent vessel occlusion without simultaneous endosaccular coiling of the aneurysm is the primary intent of the procedure • Contraindication to endovascular treatment, angiography or anesthesia
Design Schedule of evaluation following endovascular intervention
Primary end point (recurrence rate) Angiographic recurrence (6 months or 18 months), with or without retreatment (independent core lab) SAH or mass effect Secondary end point (safety) Procedural safety Mortality rate Morbidity rate, possibly or probably related to aneurysm or its treatment (Adjudication Committee) Outcomes
Randomization - Recruitment Stats TOTAL Subjects : 178; TOTAL Sites : 26 Semptember 15 2010
Randomization - Recruitment Stats List of Sites TOTAL non-US : 10 TOTAL United States : 16 The site in red has withdrawn its participation
Randomization - Recruitment Stats Performance of Sites per Country
Demographics PRET-1; N = 91 PRET-2; N = 87
Target Aneurysm Parameters PRET-1; N = 91 PRET-2; N = 87
Severity Attribution Adverse Events AE Committee review on June 4, 2010 (145 enrolled): 48 Validated AEs
Adverse Events Causality Attribution Categories: RT-S; strictly related to treatment: any M&M associated with a procedural event or complication. RT-P; possibly related to treatment: any M&M occuring within 30 days RA; related to aneurysm U; unrelated to the aneurysm or its treatment
Adverse Events Severity/Causality distribution
Randomization – Problems Problem preventing recruitment: • Cost of Hydrocoil Problems slowing recruitment: * • Not every eligible patient is recruited • Competition with other trials • Competition with other devices